非小细胞肺癌免疫治疗的临床影响因素  

Clinical influencing factors of immunotherapy for non-small cell lung cancer

作　　者：刘超星 严雪冰 杨梦雪 毛海燕[1] 童建东[1] Liu Chaoxing;Yan Xuebing;Yang Mengxue;Mao Haiyan;Tong Jiandong(Department of Oncology,Affiliated Hospital of Yangzhou University,Yangzhou 225000,China;Department of Clinical Medicine,Yangzhou University School of Medicine,Yangzhou 225000,China)

机构地区：[1]扬州大学附属医院肿瘤科,225000 [2]扬州大学医学院临床医学系,225000

出　　处：《国际肿瘤学杂志》2021年第12期751-754,共4页Journal of International Oncology

摘　　要：在非小细胞肺癌(NSCLC)的治疗中,以免疫检查点抑制剂为代表的免疫疗法快速发展,明确NSCLC免疫治疗的影响因素是精准化治疗的前提。在晚期NSCLC的免疫治疗过程中,老年患者能从中获得一定疗效;男性患者在单药治疗中获益更多;类固醇激素在用于肿瘤引起的相关症状时为患者不良预后因素;发生免疫相关不良事件为良性预后因素,而驱动基因突变、抗生素的使用则会降低免疫治疗疗效。In the treatment of non-small cell lung cancer(NSCLC),immunotherapies represented by immune checkpoint inhibitors are developing rapidly.It is the premise of precise treatment to clarify the influencing factors of NSCLC immunotherapy.In the course of immunotherapy for advanced NSCLC,elderly patients can obtain specific effect from immunotherapy;male patients benefit more from monotherapy;when steroid hormones are used for related symptoms caused by tumors,they are poor prognostic factors for patients.The occurrence of immune-related adverse events is a favorable prognostic factor while driving gene mutations and the use of antibiotics will reduce the efficacy of immunotherapy.

关 键 词：癌 非小细胞肺 预后 抗菌药 免疫检查点抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]